OrbiMed rings up $950M for its transatlantic biotech Fund VI

John Carroll OrbiMed has come through with a whopping $ 950 million biotech venture fund, committing anywhere from $ 10 million to a hefty $ 75 million to each of about 30 new companies. FierceBiotech ...

Sorry, pharma. Martin Shkreli’s disgrace won’t take the heat off your pricing

Tracy Staton Pharma might think that bad boy Martin Shkreli's arrest will give the rest of the industry a breather. Though Turing Pharmaceuticals' now-ex-CEO triggered a public ...

Threshold dumps two-thirds of its staff after a crushing failure

Damian Garde Threshold Pharmaceuticals, whose Merck KGaA-partnered oncology therapy failed in a pair of trials this month, is laying off the majority of its workers and rallying around ...

AstraZeneca shrugs off pharma’s emerging markets slowdown, but Lilly’s suffering

Carly Helfand After Q2's glacial emerging markets growth, industry watchers wondered just how slow pharma could go in developing countries. As it turns out, they found a way to ...

‘Lies, deceit and fraud’: Martin Shkreli blasted by the feds for Ponzi scheme

John Carroll In addition to earning global notoriety over the past few months for price gouging on old drugs, Martin Shkreli also blazed an alleged 5-year trail of fraud that includes ...

Shire prepared to walk on Baxalta talks if deal doesn’t come soon: WSJ

Carly Helfand Whether it ends in a tie-up or not, Shire's 6-month pursuit of Baxalta is about to come to a close. That's the word from a Wall Street Journal source close to ...

FDA approves Lilly and Boehringer’s take on Sanofi’s top-selling insulin

Damian Garde Partners Eli Lilly and Boehringer Ingelheim inched closer to challenging Sanofi's best-selling insulin, winning FDA approval for their take on the blockbuster Lantus ...

Mr. Mucus helps Reckitt dominate cough-and-cold space

Carly Helfand What's the key to landing your brand on the leaderboard of cough-and-cold meds? Mr. Mucus, apparently. FiercePharma News

AstraZeneca spending hundreds of millions in China, blueprints new R&D hub

John Carroll FierceBiotech News

Valeant strikes price-cutting deal with Walgreens, hoping to polish its tarnished image

Carly Helfand Valeant has been pummeled recently by drug pricing pushback, antitrust allegations and investigations into its business practices. But now, it has a new deal in hand that ...

After a 7-year odyssey at the FDA, Merck finally wins an OK for Bridion

John Carroll For the past 7 years Merck has maintained a star rating by its program for Bridion (sugammadex), remaining convinced of its big market potential and staying upbeat after ...

Mylan demands payback from Strides on plants targeted by FDA

Tracy Staton Mylan recently got hammered by the FDA in a warning letter for three plants that it acquired as part of its $ 1.75 billion acquisition of the sterile injectables business ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS